Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
McKinsey
Colorcon
Harvard Business School
Dow

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Lebrikizumab


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Lebrikizumab?

Lebrikizumab is an investigational drug.

There have been 24 clinical trials for Lebrikizumab. The most recent clinical trial was a Phase 3 trial, which was initiated on July 31st 2013.

The most common disease conditions in clinical trials are Asthma, Dermatitis, Atopic, and Dermatitis. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Eli Lilly and Company.

There are thirteen US patents protecting this investigational drug and three hundred and eighty-four international patents.

Recent Clinical Trials for Lebrikizumab
TitleSponsorPhase
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Participants Having Atopic Dermatitis (AD) That Are Not Adequately Controlled or Non-eligible for CyclosporineAlmirall, S.A.Phase 3
A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy ParticipantsEli Lilly and CompanyPhase 1
A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic DermatitisEli Lilly and CompanyPhase 3

See all Lebrikizumab clinical trials

Clinical Trial Summary for Lebrikizumab

Top disease conditions for Lebrikizumab
Top clinical trial sponsors for Lebrikizumab

See all Lebrikizumab clinical trials

US Patents for Lebrikizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lebrikizumab ⤷  Try it Free Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders Knopp Biosciences LLC (Pittsburgh, PA) ⤷  Try it Free
Lebrikizumab ⤷  Try it Free Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) ⤷  Try it Free
Lebrikizumab ⤷  Try it Free Compositions and methods for treating chronic urticaria Knopp Biosciences LLC (Pittsburgh, PA) ⤷  Try it Free
Lebrikizumab ⤷  Try it Free Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY) ⤷  Try it Free
Lebrikizumab ⤷  Try it Free Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders Knopp Biosciences LLC (Pittsburgh, PA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lebrikizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Lebrikizumab Australia AU2014287067 2033-07-12 ⤷  Try it Free
Lebrikizumab Australia AU2014306597 2033-07-12 ⤷  Try it Free
Lebrikizumab Australia AU2014306683 2033-07-12 ⤷  Try it Free
Lebrikizumab Australia AU2017276231 2033-07-12 ⤷  Try it Free
Lebrikizumab Canada CA2918035 2033-07-12 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
McKinsey
Colorcon
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.